n
Shares of the health insurer have significantly underperformed the broader market. Over the past 52 weeks, CI stock has plunged 19.3%, trailing behind the S&P 500 Indexu2019s ($SPX) 14% surge during the same time frame. Moreover, on a year-to-date (YTD) basis, CI has slumped 6.5%, trailing the SPXu2019s 16.2% rally in 2025.
n
Zooming in further, Cigna has also struggled to keep up with the SPDR S&P Health Care Services ETFu2019s (XHS) surge. The ETF rose 6.8% over the past year and rallied 14.2% on a YTD basis.
n
nn
CI stock has been under pressure this year largely due to investor concerns about its future business model, particularly around its pharmacyu2010benefit management (PBM) operations and newly announced initiatives to overhaul how drug rebates are handled. The market appears skeptical about how smoothly the transition to this new PBM structure will proceed and how it might compress margins in the near-to-medium term.
n
For the current fiscal year ending in December 2025, analysts project Cignau2019s EPS to improve 8.5% year over year (YoY) to $29.66. The company has surpassed consensus earnings estimates in three of the past four quarters, while missing the mark on one other occasion.
n
Wall Street is upbeat on CI stock. Among the 24 analysts covering the stock, the consensus rating is a u201cStrong Buy.u201d Thatu2019s based on 17 u201cStrong Buys,u201d two u201cModerate Buys,u201d four analysts are playing it safe with a u201cHold,u201d and one suggests a u201cStrong Sell.u201d
n
nn
This configuration is slightly less bullish as there were no u201cStrong Sellu201d ratings a month ago.
n
Earlier this month, TD Cowen lowered its price target on CI to $333 from $387 while keeping a u201cBuyu201d rating.
n
Cignau2019s mean price target of $336.18 represents a 30.2% premium to current price levels, and its Street-high target of $390 indicates a 51.1% upside potential.
On the date of publication, Sristi Jayaswal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. “,”symbols”:[{“symbol”:”XHS”,”symbolName”:”S&P Healthcare Services SPDR”,”symbolType”:7,”lastPrice”:”103.85″,”priceChange”:”+0.88″,”percentChange”:”+0.85%”},{“symbol”:”CI”,”symbolName”:”The Cigna Group”,”symbolType”:1,”lastPrice”:”268.00″,”priceChange”:”+9.84″,”percentChange”:”+3.81%”},{“symbol”:”$SPX”,”symbolName”:”S&P 500 Index”,”symbolType”:9,”lastPrice”:”6,846.61″,”priceChange”:”+14.18″,”percentChange”:”+0.21%”}],”related”:[{“id”:”36065758″,”title”:”AMETEK Stock Outlook: Is Wall Street Bullish or Bearish?”,”slug”:”ametek-stock-outlook-is-wall-street-bullish-or-bearish”,”feedName”:”Barchart”,”published”:”1 hour ago”,”categories”:[“STK.EQY”]},{“id”:”36065490″,”title”:”Smurfit Westrock Stock: Analyst Estimates & Ratings”,”slug”:”smurfit-westrock-stock-analyst-estimates-ratings”,”feedName”:”Barchart”,”published”:”1 hour ago”,”categories”:[“STK.EQY”]},{“id”:”36065467″,”title”:”Do Wall Street Analysts Like S&P Global Stock?”,”slug”:”do-wall-street-analysts-like-sp-global-stock”,”feedName”:”Barchart”,”published”:”1 hour ago”,”categories”:[“STK.EQY”]},{“id”:”36065427″,”title”:”Rollins Stock Outlook: Is Wall Street Bullish or Bearish?”,”slug”:”rollins-stock-outlook-is-wall-street-bullish-or-bearish”,”feedName”:”Barchart”,”published”:”1 hour ago”,”categories”:[“STK.EQY”]},{“id”:”36065335″,”title”:”Is Wall Street Bullish or Bearish on Caterpillar Stock?”,”slug”:”is-wall-street-bullish-or-bearish-on-caterpillar-stock”,”feedName”:”Barchart”,”published”:”1 hour ago”,”categories”:[“STK.EQY”]},{“id”:”36065273″,”title”:”Are Wall Street Analysts Predicting Iron Mountain Stock Will Climb or Sink?”,”slug”:”are-wall-street-analysts-predicting-iron-mountain-stock-will-climb-or-sink”,”feedName”:”Barchart”,”published”:”1 hour ago”,”categories”:[“STK.EQY”]},{“id”:”36062759″,”title”:”Lowe’s Stock: Is Wall Street Bullish or Bearish?”,”slug”:”lowe-s-stock-is-wall-street-bullish-or-bearish”,”feedName”:”Barchart”,”published”:”Wed Nov 12, 2:02AM CST”,”categories”:[“STK.EQY”]},{“id”:”36062710″,”title”:”What Are Wall Street Analysts’ Target Price for Builders FirstSource Stock?”,”slug”:”what-are-wall-street-analysts-target-price-for-builders-firstsource-stock”,”feedName”:”Barchart”,”published”:”Wed Nov 12, 1:59AM CST”,”categories”:[“STK.EQY”]},{“id”:”36062564″,”title”:”Zimmer Biomet Stock: Analyst Estimates & Ratings”,”slug”:”zimmer-biomet-stock-analyst-estimates-ratings”,”feedName”:”Barchart”,”published”:”Wed Nov 12, 1:56AM CST”,”categories”:[“STK.EQY”]}],”sourceId”:”9477365″,”media”:”text”,”thumbnail”:{“url”:”https://media.barchart.com/contributors-admin/common-images/images/S%26P%20500%20Companies/Healthcare%20(names%20A%20-%20H)/Cigna%20Group%20HQ%20phone%20-by%20JHVEPhoto%20via%20Shutterstock.jpg”,”width”:150,”height”:90,”caption”:”Cigna Group HQ phone -by JHVEPhoto via Shutterstock”},”summary”:”Although Cigna Group has lagged the broader market, analysts remain bullish about its prospects.”,”canonicalUrl”:”https://www.barchart.com/story/news/36045495/cigna-group-stock-analyst-estimates-ratings”,”slug”:”cigna-group-stock-analyst-estimates-ratings”,”sourceFeed”:”CONT2″,”categories”:[“STK.EQY”],”meta”:”N/A”,”authorBadge”:null,”raw”:{“id”:”36045495″,”title”:”Cigna Group Stock: Analyst Estimates & Ratings”,”author”:”Sristi Jayaswal”,”authorUrl”:”https://www.barchart.com/news/authors/411/sristi-jayaswal”,”authorImage”:”https://media.barchart.com/news/authors/411/avatar-Cu02SCFZG1KhkBW4.png”,”authorType”:”author”,”feed”:”SANDP”,”feedName”:”Barchart”,”feedUrl”:”https://www.barchart.com”,”published”:1762866502,”publishedTime”:”2025-11-11 13:08:22″,”updated”:”2025-11-11 13:08:22 +0000″,”image”:{“url”:”https://media.barchart.com/contributors-admin/common-images/images/S%26P%20500%20Companies/Healthcare%20(names%20A%20-%20H)/Cigna%20Group%20HQ%20phone%20-by%20JHVEPhoto%20via%20Shutterstock.jpg”,”width”:150,”height”:90,”caption”:”Cigna Group HQ phone -by JHVEPhoto via Shutterstock”},”content”:”
The Cigna Group (CI) is a major healthcare and insurance company headquartered in Bloomfield, Connecticut. The company offers a broad mix of services, including medical and dental insurance, disability and life coverage, and global health benefits delivered through its Evernorth and other business segments. Cignau2019s market capitalization currently stands at around $69 billion.
n
Shares of the health insurer have significantly underperformed the broader market. Over the past 52 weeks, CI stock has plunged 19.3%, trailing behind the S&P 500 Indexu2019s ($SPX) 14% surge during the same time frame. Moreover, on a year-to-date (YTD) basis, CI has slumped 6.5%, trailing the SPXu2019s 16.2% rally in 2025.
n
Zooming in further, Cigna has also struggled to keep up with the SPDR S&P Health Care Services ETFu2019s (XHS) surge. The ETF rose 6.8% over the past year and rallied 14.2% on a YTD basis.
n
nn
CI stock has been under pressure this year largely due to investor concerns about its future business model, particularly around its pharmacyu2010benefit management (PBM) operations and newly announced initiatives to overhaul how drug rebates are handled. The market appears skeptical about how smoothly the transition to this new PBM structure will proceed and how it might compress margins in the near-to-medium term.
n
For the current fiscal year ending in December 2025, analysts project Cignau2019s EPS to improve 8.5% year over year (YoY) to $29.66. The company has surpassed consensus earnings estimates in three of the past four quarters, while missing the mark on one other occasion.
n
Wall Street is upbeat on CI stock. Among the 24 analysts covering the stock, the consensus rating is a u201cStrong Buy.u201d Thatu2019s based on 17 u201cStrong Buys,u201d two u201cModerate Buys,u201d four analysts are playing it safe with a u201cHold,u201d and one suggests a u201cStrong Sell.u201d
n
nn
This configuration is slightly less bullish as there were no u201cStrong Sellu201d ratings a month ago.
n
Earlier this month, TD Cowen lowered its price target on CI to $333 from $387 while keeping a u201cBuyu201d rating.
n
Cignau2019s mean price target of $336.18 represents a 30.2% premium to current price levels, and its Street-high target of $390 indicates a 51.1% upside potential.
On the date of publication, Sristi Jayaswal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. “,”symbols”:[“XHS”,”CI”,”$SPX”],”related”:[{“id”:”36065758″,”title”:”AMETEK Stock Outlook: Is Wall Street Bullish or Bearish?”,”slug”:”ametek-stock-outlook-is-wall-street-bullish-or-bearish”,”feedName”:”Barchart”,”published”:”1 hour ago”,”categories”:[“STK.EQY”]},{“id”:”36065490″,”title”:”Smurfit Westrock Stock: Analyst Estimates & Ratings”,”slug”:”smurfit-westrock-stock-analyst-estimates-ratings”,”feedName”:”Barchart”,”published”:”1 hour ago”,”categories”:[“STK.EQY”]},{“id”:”36065467″,”title”:”Do Wall Street Analysts Like S&P Global Stock?”,”slug”:”do-wall-street-analysts-like-sp-global-stock”,”feedName”:”Barchart”,”published”:”1 hour ago”,”categories”:[“STK.EQY”]},{“id”:”36065427″,”title”:”Rollins Stock Outlook: Is Wall Street Bullish or Bearish?”,”slug”:”rollins-stock-outlook-is-wall-street-bullish-or-bearish”,”feedName”:”Barchart”,”published”:”1 hour ago”,”categories”:[“STK.EQY”]},{“id”:”36065335″,”title”:”Is Wall Street Bullish or Bearish on Caterpillar Stock?”,”slug”:”is-wall-street-bullish-or-bearish-on-caterpillar-stock”,”feedName”:”Barchart”,”published”:”1 hour ago”,”categories”:[“STK.EQY”]},{“id”:”36065273″,”title”:”Are Wall Street Analysts Predicting Iron Mountain Stock Will Climb or Sink?”,”slug”:”are-wall-street-analysts-predicting-iron-mountain-stock-will-climb-or-sink”,”feedName”:”Barchart”,”published”:”1 hour ago”,”categories”:[“STK.EQY”]},{“id”:”36062759″,”title”:”Lowe’s Stock: Is Wall Street Bullish or Bearish?”,”slug”:”lowe-s-stock-is-wall-street-bullish-or-bearish”,”feedName”:”Barchart”,”published”:”Wed Nov 12, 2:02AM CST”,”categories”:[“STK.EQY”]},{“id”:”36062710″,”title”:”What Are Wall Street Analysts’ Target Price for Builders FirstSource Stock?”,”slug”:”what-are-wall-street-analysts-target-price-for-builders-firstsource-stock”,”feedName”:”Barchart”,”published”:”Wed Nov 12, 1:59AM CST”,”categories”:[“STK.EQY”]},{“id”:”36062564″,”title”:”Zimmer Biomet Stock: Analyst Estimates & Ratings”,”slug”:”zimmer-biomet-stock-analyst-estimates-ratings”,”feedName”:”Barchart”,”published”:”Wed Nov 12, 1:56AM CST”,”categories”:[“STK.EQY”]}],”sourceId”:”9477365″,”media”:”text”,”thumbnail”:{“url”:”https://media.barchart.com/contributors-admin/common-images/images/S%26P%20500%20Companies/Healthcare%20(names%20A%20-%20H)/Cigna%20Group%20HQ%20phone%20-by%20JHVEPhoto%20via%20Shutterstock.jpg”,”width”:150,”height”:90,”caption”:”Cigna Group HQ phone -by JHVEPhoto via Shutterstock”},”summary”:”Although Cigna Group has lagged the broader market, analysts remain bullish about its prospects.”,”canonicalUrl”:”https://www.barchart.com/story/news/36045495/cigna-group-stock-analyst-estimates-ratings”,”slug”:”cigna-group-stock-analyst-estimates-ratings”,”sourceFeed”:”CONT2″,”categories”:[“STK.EQY”],”meta”:null,”authorBadge”:null},”barchartAuthor”:{“id”:0,”following”:false},”contributorsServiceCategories”:[“Equities/Stocks”],”isBarchartAuthor”:true,”isContributorOrSyndicated”:false,”isPressRelease”:false,”isSponsoredContent”:false,”shouldLoadMoreNews”:true,”displayCaption”:true,”isFuturesArticle”:false,”shouldShowPlus500Ad”:false,”shareLink”:”https://www.barchart.com/share/news/36045495/cigna-group-stock-analyst-estimates-ratings”}” data-ng-controller=”NewsItem.newsItemCtrl as vm” data-ng-init=”shareLink=’https://www.barchart.com/share/news/36045495/cigna-group-stock-analyst-estimates-ratings'”>
Sristi Jayaswal – Barchart – Tue Nov 11, 7:08AM CST Columnist
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here

Cigna Group HQ phone -by JHVEPhoto via Shutterstock
The Cigna Group (CI) is a major healthcare and insurance company headquartered in Bloomfield, Connecticut. The company offers a broad mix of services, including medical and dental insurance, disability and life coverage, and global health benefits delivered through its Evernorth and other business segments. Cigna’s market capitalization currently stands at around $69 billion.
Shares of the health insurer have significantly underperformed the broader market. Over the past 52 weeks, CI stock has plunged 19.3%, trailing behind the S&P 500 Index’s ($SPX) 14% surge during the same time frame. Moreover, on a year-to-date (YTD) basis, CI has slumped 6.5%, trailing the SPX’s 16.2% rally in 2025.
Zooming in further, Cigna has also struggled to keep up with the SPDR S&P Health Care Services ETF’s (XHS) surge. The ETF rose 6.8% over the past year and rallied 14.2% on a YTD basis.

CI stock has been under pressure this year largely due to investor concerns about its future business model, particularly around its pharmacy‐benefit management (PBM) operations and newly announced initiatives to overhaul how drug rebates are handled. The market appears skeptical about how smoothly the transition to this new PBM structure will proceed and how it might compress margins in the near-to-medium term.
For the current fiscal year ending in December 2025, analysts project Cigna’s EPS to improve 8.5% year over year (YoY) to $29.66. The company has surpassed consensus earnings estimates in three of the past four quarters, while missing the mark on one other occasion.
Wall Street is upbeat on CI stock. Among the 24 analysts covering the stock, the consensus rating is a “Strong Buy.” That’s based on 17 “Strong Buys,” two “Moderate Buys,” four analysts are playing it safe with a “Hold,” and one suggests a “Strong Sell.”

This configuration is slightly less bullish as there were no “Strong Sell” ratings a month ago.
Earlier this month, TD Cowen lowered its price target on CI to $333 from $387 while keeping a “Buy” rating.
Cigna’s mean price target of $336.18 represents a 30.2% premium to current price levels, and its Street-high target of $390 indicates a 51.1% upside potential.
On the date of publication, Sristi Jayaswal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.